Kornimate/medical-research-clean huggingface dataset:
face perception vs. memory training to improve face recognition in developmental prosopagnosia

Conditions: Developmental Prosopagnosia

Summary: the goal of this study is to test the effectiveness of two experimental training programs aimed at improving face processing in developmental prosopagnosia (perception training, memory training) in comparison to an active control. the investigators will use a longitudinal design and randomize developmental prosopagnosics to three parallel arms: active control, perception training and memory training.

the investigators propose a longitudinal design with three parallel arms: active control, perception training and memory training. to maximize power, developmental prosopagnosics (dps) in the active control group will be subsequently be offered training. pre-training/control assessments will be performed and within 2 weeks, dps will be randomized to one of the three training conditions. next, all dps will complete 6-weeks of their assigned intervention. the research assistant will provide coaching at least once per week. dps will be assessed within two weeks of training completion and after a 12-week no-contact period. for those in the active control group, the no-contact period will serve to wash out any placebo effect and assessment 3 will be used as their new baseline. these dps will then be randomized to perception or memory training. assessments will then be given to these dps within a week after intervention completion and after a 12 weeks no-contact period.

Eligibility criteria:
inclusion criteria: * aged 18-90 * have lifelong histories of face recognition difficulties that impact everyday life (i.e., not associated with some event such as a stroke, seizure, etc) * score \> 2 standard deviations below the mean on the famous faces test and cambridge face memory test. this is in line with our previous studies and others in the literature. exclusion criteria: * history of a significant neurological disorder including hydrocephalus, stroke, moderate to severe traumatic brain injury (tbi), severe neuromuscular diseases, or severe hypoxia due to cardiac arrest. * participants with a history of mild tbi or simple concussion will not be excluded as long as it was \> 6 months ago and as long as they have not had repeated concussions (\>5). * participants will be excluded if they have impairments that interfere with cognitive performance, such as uncorrected hearing or vision, lack of english proficiency, musculoskeletal or other issues. * additionally, participants will be excluded if they have psychiatric disorders, such as schizophrenia, major depressive disorder, bipolar disorder, chronic intractable obsessive-compulsive disorder, or agoraphobia. * participants with a diagnosis of adhd will be included as long as their medication has been consistent for the past 6 months. * participants who are currently dependent on alcohol or other substances will be excluded, as this may negatively impact cognitive performance. * participants who currently are, or within the last 6 months, participating in a behavioral or pharmacological intervention will be excluded.
trial evaluating efficacy and safety of bevacizumab (avastin®/zeribev®) in patients with covid-19 infection, nested in the corimmuno-19 cohort

Conditions: COVID19 Pneumonia

Summary: bevacizumab, zeribev® (pfizer)/avastin® (roche) 25 mg/ml ®, is a recombinant humanised monoclonal igg1 antibody it seems interesting to use bevacizumab in severe patients infected with sars-cov-2 requiring hospitalization in conventional unit or in icu. this protocol corimuno19-beva will evaluate the efficacy and safety of avastin®/ zeribev® (bevacizumab) covid-19 patients hospitalized in conventional units. this phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of avastin®/ zeribev® (bevacizumab) alone versus standard of care (soc) in patients hospitalized in conventional units.


Eligibility criteria:
inclusion criteria: * patients requiring more than 3l/min of oxygen * who progression scale = 5 to 8 exclusion criteria: * patients in 9 who progression class * patients with exclusion criteria to the corimuno-19 cohort. * hypersensitivity to bevacizumab or to any of their excipients. * pregnancy * active cancer with undergoing treatment * oxygen patient requiring long-term oxygen before hospitalization * patient already included in a therapeutic trial; however, inclusion should be discussed case by case with the trial coordinator. * contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery. * hypersensitivity to the active substance or one of the excipients
phase iii study of edasalonexent in boys with duchenne muscular dystrophy

Conditions: Muscular Dystrophy, Duchenne

Summary: the polarisdmd study is a phase 3, global study to evaluate the efficacy and safety of edasalonexent in pediatric patients with a genetically confirmed diagnosis of dmd. male patients from 4-7 years of age (up to 8th birthday) will be enrolled. edasalonexent is an orally administered small molecule that inhibits nf-kb, which is the key link between loss of dystrophin and disease pathology and plays a fundamental role in the initiation and progression of skeletal and cardiac muscle disease in dmd.

the study includes a 52-week, randomized, double-blind, placebo-controlled period, followed by a 2-week follow- up. approximately 125 boys with dmd will be enrolled in this trial, with 2 boys receiving edasalonexent for every 1 boy receiving placebo. following completion of the treatment period, patients may elect to continue in a separate open-label extension study.

Eligibility criteria:
inclusion criteria: * written consent/assent by patient and/or legal guardian as per regional and/or institutional review board (irb)/independent ethics committee (iec) requirements * diagnosis of dmd based on a clinical phenotype with increased serum creatine kinase (ck) and documentation of mutation(s) in the dystrophin gene known to be associated with a dmd phenotype * able to perform stand from supine without assistance in ≤ 10 seconds * able to perform the 10mwt and 4-stair climb * followed by a doctor or medical professional who coordinates duchenne care on a regular basis and willingness to disclose patient's study participation with medical professionals exclusion criteria: * use of corticosteroids within 24 weeks prior to day 1; use of inhaled, intranasal, and topical corticosteroids is permitted * use of another investigational drug, idebenone, or dystrophin-focused therapy within 4 weeks. exception: patients who have received at least 24 weeks of a stable dose of eteplirsen prior to day 1, and expected to continue treatment, will be eligible * use of the following within 4 weeks prior to day 1: immunosuppressive therapy, warfarin, phenytoin, s mephenytoin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus, tacrolimus, or paclitaxel * use of human growth hormone within 3 months prior to day 1 * other prior or ongoing significant medical conditions

Keywords: muscular dystrophies musculoskeletal diseases neuromuscular diseases duchenne muscular dystrophy dmd dystrophin dystrophy duchenne
the incidence of extended-spectrum β-lactamase (esbl) klebsiella pneumonia in patient on renal replacement therapy

Conditions: End-stage Renal Disease

Summary: the prevalence of esbl klebsiella pneumonia was higher in patient with renal replacement therapy.


Eligibility criteria:
inclusion criteria: * the age of patient was between 18 yrs and 79 yrs. * the patient who showed klebsiella pneumonia in 1st culture result of any site during hospitalization exclusion criteria: * the level of serum albumin was below 2.0 or over 5.0 * the level of ast or alt was 2 times of normal level or the level of bilirubin was over 2.0 mg/dl during 1month. * the level of body mass index was below 15 or over 30 * pregnancy

Keywords: end-stage renal disease renal replacement therapy
effects of neural mobilization on respiratory parameters in chronic neck pain

Conditions: Neck Pain; Respiratory

Summary: objective: neural mobilization (nm) is commonly used to treat nerve disorders, and it is useful for disorders associated with neck and arm pain. this study aimed to determine the effects of nm on respiratory function in patients with chronic neck pain. methods: overall, 26 patients with neck pain were randomly assigned to two groups: nm or control. in these participants, respiratory function and active cervical range of motion were assessed before and after intervention. furthermore, the participants were provided a visual analog scale (vas) and fremantle neck awareness questionnaire (frenaq). each participant underwent 15 treatment sessions (5 days per week for 3 weeks). further, in the nm group, in addition to conventional treatment, 10 sessions of neural mobilization were performed.


Eligibility criteria:
inclusion criteria: * individuals aged 25-65 years, * those with neck pain for \>3 months * those with complaints of pain, tension * numbness on neurodynamic nerve tests exclusion criteria: * individuals with spinal stenosis, * neurological diagnosis, malignancy, * upper extremity vascular problems, * osteoporosis, * pregnancy, * history of newly repaired peripheral nerves, * inflammatory processes, * cervical spine and upper extremity surgeries, * conditions affecting lung capacity (such as asthma, bronchitis, and diabetes mellitus)
ultrasound markers of systemic inflammation

Conditions: Inflammation Process; Endothelial Dysfunction; Vasomotor Arterial Disorder; Vascular Dilation; Swelling; Hand

Summary: the aim of this study was to measure whether the flow rate through the brachial artery and inflammatory markers were associated with the development of tissue edema in the surgical intensive care unit patients.

the study was performed using a ultrasound machine with linear probe settings at 50 mm depth and 40 decibel \[db\] gain that did not change during the study. the probe was placed on vascular ultrasound measurement. the diameter of the brachial artery in the middle of the upper arm and the flow rate through the artery was measured on postoperative days 1 and 2. the presence of the edema was measured above the 3rd metacarpal bone as the distance from the skin surface to the periosteum. an average of three assessments was shown. patient's age, body mass index (bmi), type of admission, white blood cells (wbc), c-reactive protein (crp), and procalcitonin (pct) were also registered.

Eligibility criteria:
inclusion criteria: * adults over 18 years of age * postoperative surgical patients * signed informed consent exclusion criteria: * refusal to give informed consent * a previous thromboembolic event of the brachial artery * acute infection of the upper extremity

Keywords: intensive care, surgical ultrasonography, doppler inflammation
waveform and spectral characteristics of perioperative wheezing

Conditions: Respiratory Sounds; Thoracic Surgery

Summary: with the aid of computerized sound analysis, digital acoustic monitoring could provide a more sensitive, specific, and quantifiable indicator for perioperative respiratory abnormalities including wheezing. it is probable that the digital stethoscope has utility in the detection, monitoring, and resolution following treatment of acoustic changes characteristic of turbulent respiratory gas flow due to wheezing and/or the incomplete resolution of atelectasis following the re-initiation of ventilation in a collapsed lung.

anesthesiologists still rely on use of a conventional stethoscope to detect abnormal breath sounds during and after surgery - this process is labor intensive, intermittent, relies on human experience and thus is highly subjective. in fact, even for the most basic assessments, e.g. endobronchial intubation, human auscultation is unreliable.1 digital stethoscopes are able to both amplify and digitize airway sounds and also provide a mechanism to record and analyze them for features undetectable by a human. several small, pilot studies have shown that acoustic waveforms from the lungs produce characteristic spectral patterns in specific pulmonary pathophysiologic states. at this time, there are no studies that examine the acoustic patterns specific to perioperative wheezing or lung re-expansion. with the aid of computerized sound analysis, digital acoustic monitoring could provide a more sensitive, specific, and quantifiable indicator for perioperative respiratory abnormalities including wheezing. it is probable that the digital stethoscope has utility in the detection and monitoring of acoustic changes characteristic of turbulent respiratory gas flow due to wheezing and/or the incomplete resolution of atelectasis following the re-initiation of ventilation in a collapsed lung. in addition, treatment of perioperative wheezing with an inhaled bronchodilator may lead to resolution of wheezing and this response to treatment may also be monitored using waveform and spectral characteristics of the acoustic patterns from the digital stethoscope.

Eligibility criteria:
inclusion criteria: patients scheduled for either: 1. open thoracic or video-assisted thoracoscopic surgery under general anesthesia requiring one-lung ventilation 2. abdominal surgery with a known history of chronic obstructive pulmonary disease (as documented in the electronic medical record) exclusion criteria: * emergency surgery * surgery requiring the use of transesophageal echocardiography * refusal of informed consent * pregnancy * esophageal surgery * lung transplantation * contraindications for placement of esophageal stethoscope including esophageal varices strictures, motility disorders, diverticula or a history of prior esophageal injury or surgery * age less than 18 years old * prisoner
effects of low molecular weight heparin versus dabigatran on platelet aggregation in patients with stable coronary artery disease

Conditions: Coronary Disease

Summary: anticoagulation with heparin is indicated in several situations, such as acute coronary disease (in combination with antiplatelet therapy) for the prevention and treatment of venous thromboembolism and situations with high risk of thromboembolism. recently, the latest trials on anticoagulation for stroke prevention on atrial fibrillation have shown an increased risk for acute mycardial infarction on patients submitted to new oral anticoagulants, such as dabigatran. the mechanism is still unclear, however, in this context, some previous studies about interaction between anticoagulants ( mainly heparin) and platelet aggregation have shown conflicting results: while some suggest an inhibitory effect of heparin on platelet function, others suggest that heparin could promote an increase in platelet activation. the present study aims to assess the effects of the lmwh enoxaparin and direct thrombin inhibitor, dabigatran, on platelet aggregation, studied and compared by different methods in patients with chronic coronary artery disease (cad).

this is a prospective and open study. we will include 29 patients with chronic cad, stable, using asa. all patients will receive the same medications in effective doses recommended at each stage of the study, so that every individual is his self-control, the enoxaparin will be administrated at a dose of 1mg/kg twice a day and dabigatran at a dose of 150mg twice a day. study design: phase 1 : there will be a first collection of blood samples from all patients at baseline for laboratory tests, then the patient will receive dabigatran for 5 days and laboratory tests including platelet aggregation will be made, among others. after a 30 days washout period, enoxaparin will be administrated for 5 days and in the 6st day, the same laboratory tests, including platelet aggregation, will be performed.

Eligibility criteria:
inclusion criteria: age \> 18 years old coronary artery disease, defined as previous myocardial infarction and/or coronary angioplasty and/or coronary artery bypass graft (cabg) surgery and/or coronariography showing obstruction of at least 50 % in one of major epicardial vessels treatment with acetylsalicylic acid (asa) 100 mg/day exclusion criteria: use in the last 7 days of oral anticoagulant or any other antiplatelet drug beside asa active bleeding pregnancy or woman of childbearing age without contraceptive method hemoglobin \ 50 %, platelets \ 500.000/mm3; creatinin clearance \< 50 ml/minute percutaneous coronary intervention (pci) on the last 30 days before randomization (or pci on the last year when drug-eluted stents are used); cabg surgery on the last 90 days; acute coronary syndrome on the last 60 days active malignant neoplasm active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any time in life refuse to participate in the study

Keywords: platelet function; dabigatran;enoxaparin
efficacy and safety of fty720 in patients with relapsing multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: to provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of fty720 in japanese patients with relapsing multiple sclerosis (ms)


Eligibility criteria:
inclusion criteria: * male and female patients aged 18-60 * patients with a diagnosis of multiple sclerosis exclusion criteria: * patients with a history or presence of chronic disease of the immune system other than ms * patients with a history or presence of malignancy, pulmonary or heart disease, etc. * pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply

Keywords: fty720, ms
use of virtual reality in children undergoing surgery

Conditions: Child, Only

Summary: aim: early mobilization and exercise after surgery are very important to reduce the impact on lung function. the aim of this study was to compare the effects of early mobilization with virtual reality and conservative physiotherapy methods on pulmonary function, dyspnea, exercise capacity, pain, and kinesiophobia in children undergoing surgery. methods: the study included 27 children aged 5-18 years who underwent surgery. among the children randomly divided into two groups, the control group (n = 14) received physiotherapy for 40 min twice a day for 3 days in the hospital after surgery, and the children were mobilized in and out of bed. in the virtual reality group (n = 13), in addition to physiotherapy practices, children were allowed to play virtual reality games for 20 min twice a day. respiratory function, exercise capacity, and pain assessment were performed before surgery and before discharge.

aim: early mobilization and exercise after surgery are very important to reduce the impact on lung function. the aim of this study was to compare the effects of early mobilization with virtual reality and conservative physiotherapy methods on pulmonary function, dyspnea, exercise capacity, pain, and kinesiophobia in children undergoing surgery. methods: the study included 27 children aged 5-18 years who underwent surgery. among the children randomly divided into two groups, the control group (n = 14) received physiotherapy for 40 min twice a day for 3 days in the hospital after surgery, and the children were mobilized in and out of bed. in the virtual reality group (n = 13), in addition to physiotherapy practices, children were allowed to play virtual reality games for 20 min twice a day. respiratory function, exercise capacity, and pain assessment were performed before surgery and before discharge.

Eligibility criteria:
inclusion criteria between the ages of 5 and 18 undergone surgery for inguinal hernia, undescended testicle, hydrocele, cord cyst, umbilical hernia, circumcision, and distal hypospadias exclusion criteria children have visual and auditory sensory problems who required immobilization after surgery and had a chronic disease that would affect pulmonary function

Keywords: child general surgery virtual reality
double bypass versus stent-treatment in irresectable pancreatic cancer

Conditions: Pancreatic Cancer; Periampullary Tumor

Summary: double bypass (hepaticojejunostomy + gastrojejunostomy) is compared to stent strategy in patients planned for curative pancreatic resection in whom peroperative findings makes resection impossible.


Eligibility criteria:
inclusion criteria: 1. preoperatively * patients with stent treated tumor in the pancreatic head or periampullary planned for pancreaticoduodenectomy * the patient jaundice should have worn off and there should be no signs of duodenal obstruction * the patient has given informed consent after verbal and written information in accordance with approved ethics application * the patient has no anatomical conditions making endoscopic therapy impossible such as previous billroth ii or gastric bypass. 2. intraoperatively * peroperative findings of of carcinomatosis, metastases or local irresectability who oppose radical surgery * surgical double bypass should be technically feasible * the patient has given informed consent after verbal and written information in accordance with approved ethics application exclusion criteria: * peroperative signs of dysfunction on biliary stent * peroperative findings of gastric outlet obstruction * surgical double bypass not technically feasible

Keywords: surgical bypass hepaticojejunostomy gastrojejunostomy biliary stent enteral stent
intrago-intraoperative radiotherapy for glioblastoma - a phase i/ii study

Conditions: Glioblastoma Multiforme

Summary: glioblastoma multiforme (gbm) is a disease with an extremely poor prognosis. despite surgery and radiochemotherapy, the tumors are likely to grow back very quickly. intraoperative radiotherapy (iort) may improve local control rates while sparing healthy tissue (giordano et al. 2014). iort takes place before cranioplasty directly after gross (or subtotal) tumor resection. several past studies on iort for gbm conducted in japan and spain have yielded encouraging results (sakai et al. 1989; matsutani et al. 1994; fujiwara et al. 1995; ortiz de urbina et al. 1995). however, the full potential of the procedure is to date largely unexplored as most previous studies used forward-scattering (electron-based) irradiation techniques, which frequently led to inadequately covered target volumes. with the advent of the spherically irradiation devices such as the intrabeam® system (carl zeiss meditec ag, oberkochen, germany), even complex cavities can be adequately covered with irradiation during iort. however, there is no data on the maximum tolerated dose of iort with low-energy x-rays as generated by this system. the intrago i/ii study aims to find out which dose of a single shot of radiation, delivered intraoperatively direct after surgery, is tolerable for patients with gbm. a secondary goal of the study is to find out whether the procedure may improve survival rates.


Eligibility criteria:
inclusion criteria: * histologically confirmed glioblastoma multiforme in frozen sections * age ≥50 years * karnofsky performance index ≥ 50% * informed consent * adequate birth control (e.g., oral contraceptives) exclusion criteria: * astrocytoma ≤ who grade iii * gliomatosis cerebri * multifocal lesions * infratentorial localization * previous cranial radiation therapy (any location) * uncontrolled intercurrent illnesses including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. * contraindications for general anaesthesia * bleeding or clotting disorders * contraindications for mri or ct scans * pregnant or breastfeeding women

Keywords: glioblastoma multiforme high-grade glioma malignant glioma iort